Sharenet Sites 
Sharenet Sites
Notification of major interest in Mediclinic International plc shares
Mediclinic International plc
(Incorporated in England and Wales)
Company Number 8338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
6 April 2018
Notification of Major Interest in Mediclinic International plc shares
1a. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are MEDICLINIC INTERNATIONAL PLC
attached:
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Details of person subject to the notification obligation
Name PUBLIC INVESTMENT CORPORATION SOC LIMITED
City and country of registered office (if applicable) PRETORIA, SOUTH AFRICA
4. Full name of shareholder(s) (if different from 3.)
Name N/A
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or
reached: 05/04/2018
6. Date on which issuer notified (DD/MM/YYYY): 06/04/2018
7. Total positions of person(s) subject to the notification obligation
% of voting rights
% of voting rights through financial in- Total number of
attached to shares struments Total of both in % voting rights of
(total of 8. A) (total of 8.B 1 + 8.B 2) (8.A + 8.B) issuer
Resulting situation
on the date on which
threshold was
crossed or reached 7.989% 7.989% 737 243 810
Position of previous
notification (if 8.064% 8.064%
applicable)
8. Notified details of the resulting situation on the date on which the threshold was crossed or
reached
A: Voting rights attached to shares
Class/type of Number of voting rights % of voting rights
shares
ISIN code (if possible) Direct Indirect Direct Indirect
(Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive
2004/109/EC) (DTR5.1) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC)
(DTR5.2.1) (DTR5.2.1)
58 894 769 7.989%
SUBTOTAL 8. A 58 894 769 7.989%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Number of voting rights % of voting rights
Type of financial Expiration date Exercise/ that may be acquired if
instrument Conversion Period the instrument is
exercised/converted.
SUBTOTAL 8. B 1 NIL NIL
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive
2004/109/EC (DTR5.3.1.1 (b))
Type of financial Expiration Exercise/ Physical or Number of voting
instrument date Conversion cash settlement rights % of voting rights
Period
SUBTOTAL NIL NIL
8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not
control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity
(please add additional rows as necessary)
% of voting rights
% of voting rights if it through financial in- Total of both if it
equals or is higher struments if it equals equals or is higher
than the notifiable or is higher than the than the notifiable
threshold notifiable threshold threshold
Name
PUBLIC INVESTMENT
CORPORATION SOC 7.989% 7.989%
LIMITED
10. In case of proxy voting, please identify:
Name of the proxy holder N/A
The number and % of voting rights held N/A
The date until which the voting rights will be held N/A
11. Additional information
3
Name: DEVILLIERS MAKONKO
E-Mail: Devilliers.Makonko @pic.gov.za
TEL: +27 12 742 3578
Place of completion PRETORIA, SOUTH AFRICA
Date of completion 06 April 2018
Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary
listings on the JSE in South Africa and the NSX in Namibia.
For further information please contact:
Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Company Secretary, Link Company Matters Limited
Victoria Dalby
+44 (0)207 954 9600
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
4
Date: 06/04/2018 01:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
